|
COOP scores. |
||||||||
| Baseline |
SAMe |
Celecoxib |
||||||
|
|
||||||||
| Variable |
N+ |
Mean |
(SD) |
Mean |
(SD) |
Mean |
(SD) |
Stdif. |
|
|
||||||||
| Total Score |
46 |
48.7 |
(8.7) |
39.9* |
(9.3) |
39.8* |
(11.3) |
-0.01 |
| Physical Condition |
46 |
56.2 |
(20.4) |
51.7 |
(19.1) |
51.3 |
(18.2) |
-0.02 |
| Emotional Condition |
46 |
37.6 |
(16.1) |
33.5 |
(17.9) |
34.8 |
(17.6) |
0.07 |
| Daily Work |
46 |
47.1 |
(17.0) |
34.3* |
(14.4) |
33.9* |
(15.7) |
-0.03 |
| Social Activities |
46 |
31.4 |
(15.4) |
29.1 |
(13.1) |
29.6 |
(15.6) |
0.02 |
| Pain |
46 |
70.5 |
(14.1) |
53.0* |
(15.9) |
50.9* |
(19.2) |
-0.10 |
| Change in Condition |
46 |
65.2 |
(13.3) |
49.1* |
(16.7) |
47.8* |
(18.6) |
-0.05 |
| Overall Condition |
46 |
50.0 |
(16.1) |
44.3* |
(16.3) |
41.3* |
(16.0) |
-0.19 |
| Social Support |
46 |
39.0 |
(24.6) |
29.6* |
(18.3) |
32.6 |
(18.1) |
0.17 |
| Quality of Life |
46 |
41.0 |
(13.9) |
34.3* |
(16.1) |
36.1 |
(13.1) |
0.11 |
|
Stdif: Standardized difference scores – positive numbers indicate a better response with SAMe +Sample sizes are less than 57 due to missing data in either Phase 1 or Phase 2. *Difference between baseline and treatment is statistically significant (p < 0.05). No statistically significant differences were observed between SAMe and Celecoxib | ||||||||
Najm et al. BMC Musculoskeletal Disorders 2004 5:6 doi:10.1186/1471-2474-5-6 |
||||||||